NEW YORK, April 9, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Allergan Inc. (NYSE: AGN), Accuray Incorporated (NASDAQ: ARAY),
Cerus Corporation (NASDAQ: CERS), Galena Biopharma, Inc. (NASDAQ:
GALE), and ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ). Private wealth
members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Allergan Inc. Analyst Notes
On April 4, 2014, Allergan Inc.
(Allergan) announced that David
Pyott, Chairman of the Board and CEO, and Jeff Edwards, Executive Vice President, Finance
and Business Development, CFO, will discuss the Company's Q1 2014
results on May 7, 2014. According to
the Company, a live webcast of the call can be accessed through the
Company website starting at 8:00 a.m.
PT, and a replay of the discussion will also be available at
the website shortly after the call for one week. The full analyst
notes on Allergan Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/04092014/AGN/report.pdf
--
Accuray Incorporated Analyst Notes
On March 27, 2014, Accuray
Incorporated (Accuray) announced that it has received Shonin
approval from the Japanese Ministry of Health, Labor and Welfare
(MHLW) to market the CyberKnife® M6™ System to treat radiation
therapy patients. According to Accuray, the system will be marketed
as the "CyberKnife M6 Series" in Japan, offering the widest range of motion and
highest-precision conformal delivery available and enabling
patients to lie comfortably and breathe freely while receiving
precise, high dose radiation therapy in a relatively short number
of treatments, reducing side effects and preserving quality of
life. Additionally, the Company stated that the CyberKnife System
enables physicians to precisely maximize dose, minimize side
effects and maximize patient comfort. Juki
Hozumi, President and General Manager of Japan at Accuray, commented, "At Accuray, we
understand the priority that our customers place on advanced
medical technology and patient comfort. We are committed to
excellence in service, support and education that will enable our
customers to optimize their use of our leading-edge tumor
treatments long-term." The full analyst notes on Accuray
Incorporated are available to download free of charge at:
http://www.AnalystsReview.com/04092014/ARAY/report.pdf
--
Cerus Corporation Analyst Notes
On March 25, 2014, Cerus
Corporation (Cerus) announced that Dr. Frank Witney, President and CEO of Affymetrix,
has joined the Company's Board of Directors and the Compensation
Committee. According to the Company, Dr. Witney will fill the board
seat vacated by B. J. Cassin upon
his retirement from the board last December
31, 2013. Commenting on the appointment, Obi Greenman,
President and CEO of Cerus, stated, "On behalf of the management
team and board of directors, I am delighted to welcome Dr. Witney
to Cerus. His extensive commercial experience in the life science
space will serve as a valuable asset to the Company as we prepare
for a possible launch of our INTERCEPT platelet and plasma products
in the U.S." The full analyst notes on Cerus Corporation are
available to download free of charge at:
http://www.AnalystsReview.com/04092014/CERS/report.pdf
--
Galena Biopharma, Inc. Analyst Notes
On April 4, 2014, Galena
Biopharma, Inc.'s (Gale Biopharma) stock declined 4.20%, closing at
$2.28. The Company's stock went down
by 10.94% over the past three-day trading period, compared to the
Nasdaq Composite which dipped 3.29% during the same trading period.
The full analyst notes on Galena Biopharma, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/04092014/GALE/report.pdf
--
ZELTIQ Aesthetics, Inc. Analyst Notes
On April 3, 2014, ZELTIQ
Aesthetics, Inc. (ZELTIQ) reported that it has launched the
CoolSmooth™ applicator, the latest addition to the successful
CoolSculpting® range of applicators. ZELTIQ stated that CoolSmooth
is the first and only non-surgical solution for reducing fat on the
outer thighs, with a comfortable design that adjusts to fit each
unique patient. According to the Company, when combined with
CoolFit™ which is designed to treat the inner thigh, CoolSmooth now
provides patients the opportunity to treat the entire thigh area.
Commenting on the launch, Mark
Foley, President and CEO of ZELTIQ, stated, "The
introduction of the CoolSmooth applicator provides a new solution
to individuals who struggle to reduce fat in the thigh area, a
difficult-to-treat part of the body. Through our newest applicator,
we are excited by the opportunity to expand our current offerings
to physicians and, ultimately, the individuals who may benefit from
our unique technology. Results achieved with CoolSmooth add to the
growing body of evidence demonstrating the safety, efficacy and
long-lasting results of the CoolSculpting procedure." The full
analyst notes on ZELTIQ Aesthetics, Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/04092014/ZLTQ/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://AnalystsReview.com
SOURCE Analysts Review